- A meta-analysis of data for patients hospitalized with COVID-19 shows a survival benefit with use of renin-angiotensin-aldosterone system (RAAS) inhibitors.
- These meta-analysis results conflict with observational findings also reported in this article.
Why this matters
- Because their observational findings were not in agreement with those of their meta-analysis, the authors say that the results should still be “considered as exploratory and interpreted cautiously.”
- In keeping with many previous reports, mortality risk was increased for patients who had hypertension vs those without:
- 4.0% vs 1.1%.
- aHR, 2.12 (95% CI, 1.17-3.82).
- Patients with hypertension also had increased risk for severe/critical disease, invasive mechanical ventilation.
- Untreated hypertension also was linked to increased mortality risk vs being on treatment:
- 7.9% vs 3.2%.
- aHR, 2.17 (95% CI, 1.03-4.57).
- Patients taking RAAS inhibitors did not differ in mortality risk from those taking some other antihypertensive:
- 2.2% vs 3.6%.
- aHR, 0.85 (95% CI, 0.28-2.58).
- That finding contrasted with results of the meta-analysis of these data together with published data from 3 other Chinese groups, which showed a mortality risk reduction with RAAS inhibitor use:
- Relative risk, 0.65 (95% CI, 0.45-0.94).
- Retrospective, observational study of 2877 consecutive patients (850 with hypertension) hospitalized with COVID-19 in Wuhan, China.
- Funding: None disclosed.
- Relatively small numbers with hypertension.
- Observational, residual confounding risk.